Stephen Sugrue - DocGo Chief Officer
| DCGO Stock | USD 4.25 0.13 3.16% |
Insider
Stephen Sugrue is Chief Officer of DocGo Inc
| Age | 51 |
| Address | 35 West 35th Street, New York, NY, United States, 10001 |
| Phone | 844 443 6246 |
| Web | https://www.docgo.com |
Latest Insider Transactions
Stephen Sugrue Latest Insider Activity
Tracking and analyzing the buying and selling activities of Stephen Sugrue against DocGo stock is an integral part of due diligence when investing in DocGo. Stephen Sugrue insider activity provides valuable insight into whether DocGo is net buyers or sellers over its current business cycle. Note, DocGo insiders must abide by specific rules, including filing SEC forms every time they buy or sell DocGo'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Stephen Sugrue over six months ago Acquisition by Stephen Sugrue of 4472 shares of DocGo subject to Rule 16b-3 | ||
Stephen Sugrue over a year ago Acquisition by Stephen Sugrue of 85485 shares of DocGo subject to Rule 16b-3 | ||
Stephen Sugrue over a year ago Exercise or conversion by Stephen Sugrue of 16129 shares of DocGo subject to Rule 16b-3 |
DocGo Management Efficiency
The company has return on total asset (ROA) of 0.0658 % which means that it generated a profit of $0.0658 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0941 %, meaning that it created $0.0941 on every $100 dollars invested by stockholders. DocGo's management efficiency ratios could be used to measure how well DocGo manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of November 2024, Return On Tangible Assets is likely to grow to 0.02. Also, Return On Capital Employed is likely to grow to 0.05. At this time, DocGo's Non Currrent Assets Other are very stable compared to the past year. As of the 24th of November 2024, Other Assets is likely to grow to about 24.6 M, while Total Assets are likely to drop about 306.8 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Guy Sansone | Mednax Inc | 56 | |
| PT MBA | Enhabit | N/A | |
| CFA CFA | ModivCare | N/A | |
| John Gochnour | Pennant Group | 41 | |
| Tanya Marion | Enhabit | 50 | |
| Robin Doerr | InnovAge Holding Corp | 60 | |
| Kevin Connor | Encompass Health Corp | 53 | |
| RN MHA | InnovAge Holding Corp | 73 | |
| LLM JD | ModivCare | 54 | |
| Shirley Weis | Mednax Inc | 67 | |
| Mark Miller | Encompass Health Corp | N/A | |
| Jennifer CPA | Pennant Group | 55 | |
| Barbara CPA | InnovAge Holding Corp | 61 | |
| Maria Lozzano | InnovAge Holding Corp | 44 | |
| Cheryl VanPattan | Mednax Inc | N/A | |
| Carlos Migoya | Mednax Inc | 64 | |
| Melanie Lewis | Encompass Health Corp | N/A | |
| Grover Wray | ModivCare | 63 | |
| Ryan Kubota | InnovAge Holding Corp | N/A | |
| Olivia Patton | InnovAge Holding Corp | N/A | |
| Heath Sampson | ModivCare | 53 | |
Management Performance
| Return On Equity | 0.0941 | ||||
| Return On Asset | 0.0658 |
DocGo Inc Leadership Team
Elected by the shareholders, the DocGo's board of directors comprises two types of representatives: DocGo inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DocGo. The board's role is to monitor DocGo's management team and ensure that shareholders' interests are well served. DocGo's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DocGo's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anthony Capone, President | ||
| Ely Tendler, Secretary Counsel | ||
| James MD, CEO Board | ||
| Aaron Severs, Chief Officer | ||
| Mike Cole, Vice Relations | ||
| Lee Bienstock, Chief Officer | ||
| Andre CPA, Executive Strategy | ||
| Stanley Vashovsky, CoFounder Chairman | ||
| Mark Merlin, LLC Holdings | ||
| Ely JD, Secretary Counsel | ||
| Stephen Sugrue, Chief Officer | ||
| Norman Rosenberg, Treasurer CFO | ||
| Vrenely Munoz, Chief Officer | ||
| Eiwe Lingefors, Chief Officer | ||
| Stan Vashovsky, Chairman CoFounder | ||
| Rosemarie Milano, Vice Resources | ||
| Ben Sherman, EVP Development |
DocGo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DocGo a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0941 | ||||
| Return On Asset | 0.0658 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 401.24 M | ||||
| Shares Outstanding | 102.05 M | ||||
| Shares Owned By Insiders | 9.91 % | ||||
| Shares Owned By Institutions | 54.94 % | ||||
| Number Of Shares Shorted | 7.13 M | ||||
| Price To Earning | 17.46 X |
Pair Trading with DocGo
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DocGo position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DocGo will appreciate offsetting losses from the drop in the long position's value.Moving together with DocGo Stock
Moving against DocGo Stock
| 0.8 | FIGS | Figs Inc | PairCorr |
| 0.77 | PHG | Koninklijke Philips | PairCorr |
| 0.64 | CVS | CVS Health Corp Aggressive Push | PairCorr |
| 0.64 | EVH | Evolent Health | PairCorr |
| 0.52 | AGL | agilon health | PairCorr |
The ability to find closely correlated positions to DocGo could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DocGo when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DocGo - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DocGo Inc to buy it.
The correlation of DocGo is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DocGo moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DocGo Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DocGo can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DocGo Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DocGo. If investors know DocGo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DocGo listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.09 | Earnings Share 0.29 | Revenue Per Share 6.752 | Quarterly Revenue Growth (0.26) | Return On Assets 0.0658 |
The market value of DocGo Inc is measured differently than its book value, which is the value of DocGo that is recorded on the company's balance sheet. Investors also form their own opinion of DocGo's value that differs from its market value or its book value, called intrinsic value, which is DocGo's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DocGo's market value can be influenced by many factors that don't directly affect DocGo's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DocGo's value and its price as these two are different measures arrived at by different means. Investors typically determine if DocGo is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DocGo's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.